News

MedUni Vienna: AID/APOBECs among important factors in body’s defence against SARS-CoV-2

Together with their multifaceted action mechanisms, activation-induced cytidine deaminase (AID) and so-called APOBEC…

Uni Vienna: Bacterial survival kit to endure in soil

Soil bacteria have amazing strategies to attain energy in order to withstand stressful times

APEIRON Biologics launches next clinical trial with innovative cancer therapy APN401

Important development step for promising cell therapy

Cutanos closes first financing round with investor consortium from Austria and Germany

Max Planck spin-off develops immunotherapies through innovative platform technology

Cutanos: Targeted immune stimulation for more effective vaccines

Cutanos, a spin-off from the Max Planck Society, is developing novel vaccines and immunotherapies

Wiener Digital Health Fonds Calm/Storm Ventures auf Erfolgskurs in Europa

Calm/Storm Ventures, gegründet 2020 von den Investoren Lucanus Polagnoli, Michael Ströck und Hansi Hansmann, investierte…

Scailyte and Lexogen create a joint biomarker discovery workflow for precision medicine companies

Scailyte, a single-cell biomarker discovery company and Lexogen, a leader in RNA sequencing solutions, announce a…

CEO of Lithoz wins ‘Big Five Award of Additive Manufacturing 2021’ as world leader in ceramic 3D printing

- Dr. Johannes Homa and his company, Lithoz, recently awarded with the ‘Big Five Award of Additive Manufacturing 2021’ …

TU Wien: WWTF-Projekt: Die Physik lebender Materie

Mit Unterstützung des WWTF gründet der Physiker Sebastian Fürthauer eine neue Forschungsgruppe an der TU Wien, die sich…

Boehringer Ingelheim zeichnet a:head bio AG mit Grass Roots Innovation Prize aus

- a:head erzeugt „Mini-Gehirne“ zur Erforschung von Therapien gegen Krankheiten des zentralen Nervensystems

- Zweites…

MedUni Wien: Herzklappenfehler: Das unterschätzte Risiko einer häufigen Erkrankung

Das Auftreten eines Herzklappenfehlers wurde bisher bei PatientInnen mit chronischer Herzschwäche unterschätzt und…

Valneva Continues Ongoing Discussions with the European Commission for Inactivated COVID-19 Vaccine Candidate

Following a media article published yesterday, Valneva SE, (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine…

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.